Proinflammatory effects of iron sucrose in chronic kidney disease

Kidney International

Volumn 69, Issue 7, 2006, Pages 1259-1263

  Agarwal, R ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Inflammation; Iron; MCP 1; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; FERRIC HYDROXIDE SUCROSE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO;

AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; URINARY EXCRETION;

AGED; CHEMOKINE CCL2; CHRONIC DISEASE; FERRIC COMPOUNDS; HUMANS; INFLAMMATION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; REPRODUCIBILITY OF RESULTS;

EID: 33645508160     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000164     Document Type: Article

References (26)

1. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11: 152-176.
2. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004; 66: 144-156.
3. Nankivell BJ, Chen J, Boadle RA, Harris DC. The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 1994; 4: 1598-1607.
4. Alfrey AC. Toxicity of tubule fluid iron in the nephrotic syndrome. Am J Physiol 1992; 263: F637-F641.
5. Neale TJ, Ullrich R, Ojha P et al. Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci USA 1993; 90: 3645-3649.
6. Shah SV. Role of iron in progressive renal disease. Am J Kidney Dis 2001; 37: S30-S33.
7. Remuzzi A, Puntorieri S, Brugnetti B et al. Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney Int 1991; 39: 647-652.
8. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003; 284: F863-F869.
9. Schneider A, Panzer U, Zahner G et al. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int 1999; 56: 135-144.
10. Wakefield TW, Greenfield U, Rolfe MW et al. Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis. Thromb Haemost 1993; 69: 164-172.
11. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-866.
12. Viedt C, Orth SR. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrol Dial Transplant 2002; 17: 2043-2047.
13. Wada T, Yokoyama H, Su SB et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49: 761-767.
14. Grandaliano G, Gesualdo L, Ranieri E et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 1996; 7: 906-913.
15. Satriano JA, Shuldiner M, Hora K et al. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest 1993; 92: 1564-1571.
16. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002; 22: 479-487.
17. Lim CS, Vaziri ND. Iron and oxidative stress in renal insufficiency. Am J Nephrol 2004; 24: 569-575.
18. Zager RA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 2005; 68: 1533-1542.
19. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 65: 1802-1809.
20. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.
21. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.
22. Nath KA, Croatt AJ, Haggard JJ, Grande JP. Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int 2000; 57: 2423-2433.
23. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-923.
24. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Rapid communication. Kidney Int 2004; 65: 2108-2112.
25. Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol 2005; 288: F290-F297.
26. Clothier B, Robinson S, Akhtar RA et al. Genetic variation of basal iron status, ferritin and iron regulatory protein in mice: potential for modulation of oxidative stress. Biochem Pharmacol 2000; 59: 115-122.